Bowel Urgency and Abdominal Pain in Patients With Moderately to Severely Active Ulcerative Colitis in the Etrasimod ELEVATE UC Clinical Program: A Post Hoc Analysis

被引：0

作者：

Dubinsky, Marla C. ^{[1
]}

Chaparro, Maria ^{[2
]}

Armuzzi, Alessandro ^{[3
]}

Irving, Peter M. ^{[4
,6
]}

Allez, Matthieu ^{[5
]}

Panaccione, Remo ^{[6
]}

Goetsch, Martina ^{[7
]}

Bartolome, Lauren ^{[8
]}

Bananis, Eustratios ^{[9
]}

Wu, Joseph ^{[10
]}

Wosik, Karolina ^{[11
]}

Bhattacharjee, Abhishek ^{[12
]}

Smith, Christina C. ^{[9
]}

Sands, Bruce E. ^{[13
]}

机构：

[1] Mt Sinai Kravis Childrens Hosp, New York, NY USA

[2] Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS Princesa, Hosp Univ La Princesa, Ctr Invest Biomed Red Hepat & Digest, Madrid, Spain

[3] IRCCS Humanitas Res Hosp, Milan, Italy

[4] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England

[5] Univ Paris Cite, Hop St Louis, Paris, Ile De France, France

[6] Univ Calgary, Calgary, AB, Canada

[7] Pfizer AG, Zurich, Switzerland

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Collegeville, PA USA

[10] Pfizer Inc, Cambridge, MA USA

[11] Pfizer Canada, Kirkland, PQ, Canada

[12] Pfizer Healthcare India Pvt Ltd, Chennai, Tamil Nadu, India

[13] Icahn Sch Med Mt Sinai, New York, NY USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1164

引用

页码：S889 / S890

页数：2

共 50 条

[1] Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Sands, Bruce E.
Dubinsky, Marla C.
Kotze, Paulo G.
Vermeire, Severine
Panaccione, Remo
Long, Millie D.
Woolcott, John C.
Wu, Joseph
Mcdonnell, Aoibhinn
Goetsch, Martina
Bananis, Eustratios
Yarur, Andres J.
INFLAMMATORY BOWEL DISEASES, 2025,
[2] ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Magro, Fernando
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Danese, Silvio
Jairath, Vipul
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Branquinho, Diogo
Modesto, Irene
Feagan, Brian G.
GASTROENTEROLOGY, 2023, 164 (06) : S1092 - S1093
[3] Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Magro, F.
Peyrin-Biroulet, L.
Sands, B. E.
Danese, S.
Jairath, V.
Goetsch, M.
Bhattacharjee, A.
Wu, J.
Branquinho, D. Ferreira
Modesto, I.
Feagan, B. G.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 728 - 729
[4] Efficacy and Safety of Etrasimod in Patients With Ulcerative Colitis Stratified by Body Mass Index: A Post Hoc Analysis From the ELEVATE UC Clinical Program
Yarur, Andres J.
Long, Millie D.
Torres, Joana
Nandi, Neilanjan
Cross, Raymond K.
Abbatemarco, Arcangelo M.
Blanco, David
Niezychowski, Wojciech
Crosby, Catherine M.
Wu, Joseph
Pradeep, Gokul
Goetsch, Martina
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1026 - S1027
[5] Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Lichtenstein, Gary R.
Allegretti, Jessica R.
Loftus Jr, Edward, V
Irving, Peter M.
Banerjee, Rupa
Charabaty, Aline
Kuehbacher, Tanja
Bananis, Eustratios
Woolcott, John C.
Dalam, Alexis B.
Lazin, Krisztina
Keating, Michael
Mcdonnell, Aoibhinn
Danese, Silvio
INFLAMMATORY BOWEL DISEASES, 2025,
[6] Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
Danese, Silvio
Komori, H. Kiyomi
Ryan, Rathi D.
Cataldi, Fabio
Lee, Caroline A.
Goetsch, Martina
Siegmund, Britta
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S673 - S673
[7] Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
Feagan, Brian G.
Peyrin-Biroulet, Laurent
Sandborn, William J.
D'Haens, Geert
Panes, Julian
Yarur, Andres
Wolf, Douglas C.
Ritter, Timothy E.
Schreiber, Stefan
Sloan, Sheldon
Cataldi, Fabio
Shan, Kevin
Rabbat, Christopher J.
Chiorean, Michael
Baert, Filip
Sands, Bruce E.
Dubinsky, Marla C.
Vermeire, Severine
Goetsch, Martina
Danese, Silvio
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S516 - S517
[8] MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Sands, Bruce E.
Vermeire, Severine
Dubinsky, Marla C.
Feagan, Brian G.
Panaccione, Remo
Jairath, Vipul
Yarur, Andres J.
Chiorean, Michael V.
Panes, Julian
Goetsch, Martina
Rabbat, Christopher J.
Shah, Pooja
Wu, Joseph
Ghosh, Subrata
GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1085
[9] Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program
Regueiro, Miguel
Vermeire, Severine
Rubin, David T.
Dubinsky, Marla C.
Hart, Ailsa
Wu, Joseph
Green, Jesse
Woolcott, John C.
Gorelick, Kenneth J.
McDonnell, Aoibhinn
Lazin, Krisztina
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S817
[10] Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
Dubinsky, Marla C.
Clemow, David B.
Gibble, Theresa Hunter
Li, Xingyuan
Vermeire, Severine
Hisamatsu, Tadakazu
Travis, Simon P. L.
CROHNS & COLITIS 360, 2023, 5 (01)

← 1 2 3 4 5 →